This Emerging Markets Pharma Stock Rises 47% in 1 Year: US Sales Surge and Record Profits Power the Rally
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
CMP around Rs 3,517 (10 Sep 2026). 1-year return 46.92%, rank 37 of 101. 52W range Rs 2,330 to Rs 3,796.95. Market cap approx Rs 44,200 Cr. Q1 FY27 PAT approx Rs 334 Cr, up 31%.
Quick Answer
Ajanta Pharma is the emerging markets pharma stock behind a 1-year return of 46.92%. The share rose from around Rs 2,390 to near Rs 3,517 as US generics sales grew over 50%, India branded growth sped up and Q1 FY27 profit rose 31% to about Rs 334 crore. The latest domestic brokerage target is Rs 3,800, though US growth is guided to slow in FY27.
This emerging markets pharma stock has added approximately 47% in one year, turning Rs 1 lakh into roughly Rs 1.47 lakh. One Mumbai-based drug maker delivered a 1-year return of 46.92% as of 10 September 2026, ranking 37th in a screen of 101 large-cap and mid-cap NSE shares.
The company is Ajanta Pharma Ltd (NSE: AJANTPHARM), which sells branded medicines in India, Asia and Africa and runs a fast-growing generics business in the US. The Ajanta Pharma share price has moved from around Rs 2,390 a year ago to approximately Rs 3,517 on 10 September 2026, and the company is valued at approximately Rs 44,200 crore.
Click Here – Get Free Investment Predictions
Which Emerging Markets Pharma Stock Rose 47% in 1 Year?
Ajanta Pharma is the emerging markets pharma stock that rose 46.92% in one year, placing it 37th out of 101 screened NSE stocks. The Ajanta Pharma share price closed near Rs 3,517 on 10 September 2026, a little below the levels of around Rs 3,546 to Rs 3,579 seen earlier in the week.
The share now trades roughly 7% below its 52-week high of Rs 3,796.95, touched on 18 August 2026, and about 51% above its 52-week low of around Rs 2,330, recorded on 30 September 2025. Here is how this emerging markets pharma stock has performed across time frames in our screen:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 0.37% | 94 |
| 6 Months | 23.26% | 60 |
| 1 Year | 46.92% | 37 |
| 3 Years | 95.16% | 46 |
| 5 Years | 130.00% | 50 |
Returns are simple price changes and are not annualised. Ajanta has a face value of Rs 2 per share and did not carry out any stock split or bonus issue in the last year, so the 46.92% figure for this emerging markets pharma stock reflects genuine price appreciation.
The table also shows how uneven the path has been. The 1-month return of just 0.37% ranks 94th, which tells you the rally has paused since the August peak. Most of the one-year gain came between May and August 2026, after the share spent the previous seven months in a range of roughly Rs 2,330 to Rs 3,000.
Why Did This Emerging Markets Pharma Stock Rise 47% in 1 Year?
This emerging markets pharma stock rose because earnings kept compounding while several growth engines fired together. Revenue crossed Rs 5,000 crore in FY26, the US business grew at more than 50% in recent quarters, and India branded sales accelerated in Q1 FY27. A new obesity and diabetes partnership and steady mutual fund buying added to the move.
1. A Sharp Jump in US Generics Revenue
The US business has become the fastest-growing part of this emerging markets pharma stock. US generics revenue rose around 55% year on year to approximately Rs 505 crore in Q4 FY26, and then about 57% to approximately Rs 487 crore in Q1 FY27.
Management linked this to eight new launches in 15 months and strong traction in a seasonal flu product. For an emerging markets pharma stock, a US business growing this quickly from a low base added a second engine that investors had not fully priced in a year ago.
2. India Branded Business Picks Up Pace
India remains the largest single market for this emerging markets pharma stock, contributing about 32% of revenue. India branded sales rose approximately 24% to around Rs 509 crore in Q1 FY27, a clear step up from roughly 12% growth in Q2 FY26 and about 9.5% in Q4 FY26.
The company added around 300 medical representatives in FY26, taking the field force to approximately 3,750, and launched 26 new products in India during the year. That investment in reach is now showing up in faster prescription growth.
3. Africa Growth and the Semaglutide Opportunity
Africa is the second growth engine for this emerging markets pharma stock. Africa branded sales grew around 30% in Q1 FY27, while the institutional anti-malarial business rose approximately 83% to around Rs 70 crore. Management expects high double-digit growth from Africa in FY27.
In May 2026, Ajanta tied up with Biocon to distribute semaglutide, a diabetes and weight management drug, across 26 countries in Africa, the Middle East and Central Asia. Commercial launch is expected in late 2026 or early 2027. This deal strengthened the case for the emerging markets pharma stock as a long-term play on chronic disease demand outside India.
4. Record Q1 FY27 Profit and a Rs 32 Dividend
On 30 July 2026, Ajanta reported the strongest quarter in the history of this emerging markets pharma stock. Consolidated revenue rose 24.8% to approximately Rs 1,626 crore and net profit climbed 30.9% to around Rs 334 crore. The board also declared an interim dividend of Rs 32 per share, a payout of approximately Rs 400 crore.
The share rallied through the following weeks and touched its record high of Rs 3,796.95 on 18 August 2026. That run explains why this emerging markets pharma stock sits well inside the top half of the 1-year screen.
5. Mutual Funds Absorb a Promoter Stake Sale
On 10 June 2026, a promoter trust sold about 34.5 lakh shares, or 2.76% of the company, at an average of approximately Rs 2,968 per share. Two large domestic mutual funds bought almost the entire block of this emerging markets pharma stock. The share rose around 1.5% on the day, a sign that institutional demand was strong enough to absorb the supply.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Emerging Markets Pharma Stock Financials: Revenue and Profit Trend
The financial record behind this emerging markets pharma stock is steady rather than spectacular. Consolidated revenue has grown every quarter over the last five, and net profit has risen from approximately Rs 255 crore to around Rs 334 crore.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | EBITDA Margin | Net Profit (Rs Cr) |
|---|---|---|---|---|
| Q1 FY27 (Jun 2026) | 1,626 | 424 | 26% | 334 |
| Q4 FY26 (Mar 2026) | 1,422 | 333 | 23% | 267 |
| Q3 FY26 (Dec 2025) | 1,375 | 382 | 28% | 274 |
| Q2 FY26 (Sep 2025) | 1,354 | 328 | 24% | 260 |
| Q1 FY26 (Jun 2025) | 1,303 | 351 | 27% | 255 |
On an annual basis, revenue rose from approximately Rs 3,743 crore in FY23 to around Rs 5,453 crore in FY26, while net profit grew from about Rs 588 crore to approximately Rs 1,056 crore. FY26 was the first year in which revenue crossed Rs 5,000 crore and profit crossed Rs 1,000 crore.
Margins are the one soft spot. The EBITDA margin in Q1 FY27 was about 26.1%, down from roughly 27% a year earlier, as the lower-margin US and institutional businesses grew faster. Gross margin, however, improved to around 79.8%, which suggests pricing in the branded markets remains healthy.
Balance Sheet and Return Ratios
This emerging markets pharma stock is almost debt free, which gives it room to fund its planned FY27 capex of around Rs 400 crore from internal cash. Return on equity is approximately 27% and return on capital employed is around 34.5%, among the higher levels in listed Indian pharma.
Who Owns This Emerging Markets Pharma Stock?
Promoters still hold a large majority of this emerging markets pharma stock, but domestic institutions have steadily raised their stake. The June 2026 quarter shows the clearest shift, as the promoter block moved straight into mutual fund portfolios.
| Quarter | Promoters | FIIs | DIIs | Public |
|---|---|---|---|---|
| Jun 2026 | 63.49% | 7.68% | 21.80% | 7.03% |
| Mar 2026 | 66.25% | 8.26% | 18.36% | 7.14% |
| Dec 2025 | 66.25% | 7.97% | 18.58% | 7.20% |
| Sep 2025 | 66.25% | 8.53% | 17.90% | 7.32% |
| Jun 2025 | 66.26% | 8.86% | 17.50% | 7.38% |
DII holding rose from 17.50% to 21.80% in a year, while FII holding slipped from 8.86% to 7.68%. For this emerging markets pharma stock, rising domestic fund ownership has provided steady demand, although foreign investors have been net sellers.
Valuation: Is This Emerging Markets Pharma Stock Expensive?
At around Rs 3,517, the Ajanta Pharma share price trades at a price to earnings ratio of approximately 39 times trailing profit and about 9.7 times book value of around Rs 362 per share. The sector PE is roughly 51, so the stock is priced below the wider pharma group despite stronger return ratios.
Still, the multiple has expanded sharply. The stock traded near 28 times earnings in April 2026. Much of the 1-year gain in this emerging markets pharma stock therefore came from a re-rating, not just from profit growth of about 15% in FY26. The dividend yield is approximately 0.9%.
Key Risks for This Emerging Markets Pharma Stock
The rally has been strong, but this emerging markets pharma stock faces real risks that could slow returns from here.
1. Slower US Growth Ahead
Management of this emerging markets pharma stock has guided only mid-single-digit growth for the US business in FY27, after more than 50% growth in recent quarters. It has flagged pricing pressure and a thin pipeline of new launches. If US sales flatten, one of the key drivers of the recent rally fades.
2. Middle East and Asia Disruption
Asia branded sales fell approximately 16% in Q1 FY27 and about 10% in Q4 FY26 due to Middle East conflict and supply chain disruption. For an emerging markets pharma stock, geopolitical shocks in export markets can hit revenue quickly.
3. Margin Pressure and Valuation
EBITDA margin has slipped by around 1 percentage point year on year, and guidance is around 27%, plus or minus 1%. With this emerging markets pharma stock near 39 times earnings, any margin miss could trigger a quick pullback, as the flat 1-month return already hints.
4. Semaglutide Timing
The semaglutide launch depends on regulatory approvals in each country, which management expects over 1 to 1.5 years. Meaningful sales from this product for the emerging markets pharma stock are expected only from FY28, so delays would push out a key part of the growth story.
Download the Univest iOS App or Univest Android App to track the Ajanta Pharma share price live
Ajanta Pharma Share: Analyst View
Most analysts tracking Ajanta rate it positively, although the Ajanta Pharma share price has already run past several earlier targets. Analysts point to the India field force expansion, Africa growth and the semaglutide deal as the main supports for this emerging markets pharma stock, while flagging slower US growth.
Ajanta Pharma Share Price Target
After the Q1 FY27 results, a domestic brokerage kept an Accumulate rating with an Ajanta Pharma share price target of Rs 3,800, set when the stock traded near Rs 3,429. That implies about 8% upside from the 10 September close of around Rs 3,517.
In May 2026, another domestic brokerage set an Ajanta Pharma share price target of Rs 3,520, while a third raised its target to Rs 3,400. The Ajanta Pharma share price is already at or above both levels. At least one other domestic brokerage holds a Reduce view, citing margin headwinds and a valuation that already prices in near-term triggers.
On the chart, the 52-week high of Rs 3,796.95 acts as the nearest resistance for this emerging markets pharma stock, close to the highest target in circulation. On the downside, the June block deal price of approximately Rs 2,968 is a level many investors watch.
Conclusion
This emerging markets pharma stock rose approximately 47% in one year because Ajanta Pharma combined a sharp jump in US sales, faster India branded growth and a strong Africa business with record profits and consistent mutual fund buying. The Biocon semaglutide deal adds a longer-term growth option.
The next phase for this emerging markets pharma stock looks tougher. US growth is guided to slow, Asia remains disrupted and the valuation has moved up quickly. Investors may want to watch Q2 FY27 margins and US revenue before judging whether this emerging markets pharma stock can extend its run beyond the August high.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which emerging markets pharma stock rose 47% in 1 year?
Ans. Ajanta Pharma Ltd (NSE: AJANTPHARM) rose 46.92% in one year as of 10 September 2026. It ranked 37th among 101 screened NSE stocks, helped by strong US sales and record quarterly profit.
What is the Ajanta Pharma share price today?
Ans. The Ajanta Pharma share price closed near Rs 3,517 on 10 September 2026. The 52-week range is around Rs 2,330 to Rs 3,796.95, and the market value is approximately Rs 44,200 crore.
Why did Ajanta Pharma shares rise in the last year?
Ans. The emerging markets pharma stock rose on more than 50% growth in US generics revenue, faster India branded sales and strong Africa growth. Record Q1 FY27 profit of around Rs 334 crore and a semaglutide distribution deal with Biocon also lifted sentiment.
What is the Ajanta Pharma share price target?
Ans. After Q1 FY27, a domestic brokerage set a target of Rs 3,800 with an Accumulate rating. Other domestic brokerages set targets of Rs 3,520 and Rs 3,400 in May 2026, and at least one holds a Reduce view.
Did Ajanta Pharma announce a split or bonus in the last year?
Ans. No. This emerging markets pharma stock has a face value of Rs 2 and carried out no split or bonus issue in the past year. The 46.92% return reflects genuine price movement.
What were Ajanta Pharma Q1 FY27 results?
Ans. For this emerging markets pharma stock, revenue rose 24.8% to approximately Rs 1,626 crore and net profit grew 30.9% to around Rs 334 crore. The board declared an interim dividend of Rs 32 per share.
Is Ajanta Pharma debt free?
Ans. Ajanta Pharma is almost debt free. The emerging markets pharma stock reports return on equity of approximately 27% and return on capital employed of around 34.5%.
What are the main risks for Ajanta Pharma?
Ans. Key risks include slower US growth guided for FY27, Asia sales hit by Middle East disruption and pressure on EBITDA margins. This emerging markets pharma stock also trades near 39 times earnings, which leaves little room for a miss.
